Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter?
about
Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac DeathTargeting interleukin-1 in heart diseaseInterleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis.An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injuryThe interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats.Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure.Anakinra for myocarditis in juvenile idiopathic arthritis.Targeting danger-associated molecular patterns after myocardial infarction.MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy.The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1β, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis.Impact of an interleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury
P2860
Q26744359-55B9748E-3176-4759-87B6-7AC865BDAB72Q27009347-1445DAA6-56FB-4CEC-822D-8A3A129D1DBBQ34336131-4E9F75A9-6A3F-4040-8933-7EFB45E84ABEQ34485850-4D625C76-2984-4D22-8C9B-6AABE96C7052Q34769627-F4DCDAB9-E9E0-405B-B7F5-7C0185105EE1Q35855691-0493FFE1-9C68-4A8F-9A51-4604FB6DA863Q36885431-4B66FD53-1382-48AA-90D0-2951BD73B79DQ37369987-AD81BBA1-3E0F-4AB9-84A3-3BFC638438A3Q38595544-7C0E75E3-E6A4-4020-8808-C561E63ACFDEQ45913428-63829734-A9F1-4233-9426-C6CB3F5727B2Q47288476-DC5D7CE9-74CD-4C27-927B-854B2AF97BD1Q47350943-A6DF6101-DDCA-4CC3-B8DE-24AA01312CA8Q48429651-6A7A920C-7A50-4315-86B6-6524D172B0F0Q58915021-6298384C-E02C-440F-995C-EB49596DD27E
P2860
Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Anakinra in experimental acute ...... duration of treatment matter?
@en
Anakinra in experimental acute ...... duration of treatment matter?
@nl
type
label
Anakinra in experimental acute ...... duration of treatment matter?
@en
Anakinra in experimental acute ...... duration of treatment matter?
@nl
prefLabel
Anakinra in experimental acute ...... duration of treatment matter?
@en
Anakinra in experimental acute ...... duration of treatment matter?
@nl
P2093
P2860
P1476
Anakinra in experimental acute ...... duration of treatment matter?
@en
P2093
Amit Varma
Antonio Abbate
Fadi N Salloum
Filippo Crea
George W Vetrovec
Nicholas N Hoke
P2860
P304
P356
10.1007/S10557-008-6154-3
P577
2008-11-13T00:00:00Z